Press Detail





Biotest AG: BT-061 patent protection significantly expanded

Biotest AG / Miscellaneous

10.08.2010 10:00

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Biotest: BT-061 patent protection significantly expanded

- Compound patent granted in most important pharma markets
- Valuable asset for future partnerships

Dreieich, Germany, 10. August 2010. Biotest AG, a provider of
pharmaceutical and biotherapeutic drugs for immunological and
haematological diseases, announced today that a key patent for its unique
monoclonal antibody drug candidate BT-061 has been granted in the USA. This
antibody is being developed in phase II clinical trials in
Rheumatoid Arthritis and Psoriasis in the business unit Biotherapeutics.
The compound patent has now been granted in all three major pharma markets
- the United States, Europe and Japan.

The patent has also been granted in further five countries, including
Russia and Singapore. In several other countries the patent assessment
process is ongoing.

The BT-061 compound patent covers, among other issues, the antibody
sequence and thus provides protection against direct generic competition.
At present, the BT-061 patent portfolio consists of six international
patent families comprising granted patents and pending patent applications
which covers BT-061's novel therapeutic principle and unique mechanism of
action, and is designed to provide broad protection when fully granted.

'Biotest aims to continuously expand the patent protection for BT-061 as
well as for the use of the antibody in treating immunological diseases. The
patents granted play an important role in Biotest's development program and
in discussions with potential partners,' commented Prof. Dr. Gregor Schulz,
Chairman of Biotest AG's Board of Management.

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are
based on current plans, estimates, forecasts and expectations of the
company and are thus subject to risks and elements of uncertainty that
could result in significant deviation of actual developments from expected
developments. The forward-looking statements are only valid at the time of
publication. Biotest does not intend to update the forward-looking
statements and assumes no obligation to do so.

About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for microbiology. With a value added chain that
extends from pre-clinical and clinical development to worldwide
sales, Biotest has specialised primarily in the areas of application of
immunology and haematology. In its Plasma Protein segment, Biotest develops
and markets immunoglobulins, coagulation factors and albumins
based on human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and cancer of plasma cells. The
products of the Microbiological Monitoring segment are primarily used in
hygiene monitoring. Biotest has more than 1,900 employees worldwide. The
preference shares of Biotest AG are listed in the SDAX on the Frankfurt
stock exchange.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart


10.08.2010 Ad hoc announcement, Financial News and Press Release distributed by DGAP.
Media archive at www.medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
              Deutschland
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       investor_relations@biotest.de
Internet:     http://www.biotest.de
ISIN:         DE0005227235, DE0005227201
WKN:          522723, 522720
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Hamburg, Berlin, Düsseldorf, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------